CB03-154 not checked
Shanghai Zhimeng Biopharma, Inc.
FollowEvery change as it happens, and a Monday email
Trials
3 active
5 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “All enrolled subjects will begin with a two-week course of CB03-154 at 10 mg QD. Upon demonstrating good tolerability, the dose will be increased to 20 mg QD and continued for up to two years.”In the company’s words, NCT07238868 on ClinicalTrials.gov
- Tested for
- Focal Epilepsy (2 trials), ALS (Amyotrophic Lateral Sclerosis)
- Main trialPhase 2/3
- “The goal of this clinical trial is to learn if drug CB03-154 works to treat ALS in adults. It will also learn about the safety of drug CB03-154. The main questions it aims to answer are: * Does drug CB03-154 have an effect on delaying disease progression, improving function, and prolonging survival in adult ALS patients? * What medical problems do patients have when taking drug CB03-154? Researchers will compare drug CB03-154 to a placebo (a look-alike substance that contains no drug) to see if drug CB03-154 works to treat ALS. Participants (adult ALS patients) will: * Take drug CB03-154…”In the company’s words, NCT07082192 on ClinicalTrials.gov
Other drugs for Focal Epilepsy
- BHV-7000Biohaven · Phase 2/3
- CenobamateSK Life Science, Inc. · Phase 3
- VormatroginePraxis Precision Medicines · Phase 3
- RAP-219Rapport Therapeutics Inc. · Phase 3
- AzetukalnerXenon Pharmaceuticals Inc. · Phase 3
- NRTX-1001Neurona Therapeutics · Phase 1/2
Coming up3
- 30 Sep 2027Phase 2/3 trial completes · ClinicalTrials.gov
- Sep 2027Phase 2 trial completes · ClinicalTrials.gov
- Jan 2029Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Recruiting | 30 Sep 2027 | A Study to Evaluate the Efficacy and Safety of Different Doses of CB03-154 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS) | |
| Phase 2Recruiting | Sep 2027 | A Study to Evaluate the Safety, Tolerability, and Efficacy of CB03-154 in Adult Patients With Focal Epilepsy | |
| Phase 2Recruiting | Jan 2029 | An Open-label Study to Evaluate Safety, Tolerability, and Efficacy of CB03-154 in Subjects Diagnosed With Epilepsy | |
| Phase 1Unknown | 2 Mar 2023 | A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CB03-154 in Healthy Participants | |
| Phase 1Completed | 9 Nov 2023 | A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CB03-154 in Healthy Participants in Australia |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026